Please assess the completion status of the following clinical trial:

Trial Title: Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of multiple myeloma~  - Relapsed disease~* Must not be a candidate for stem cell transplantation, has refused transplantation, or has had stem cells collected previously~* Measurable disease, defined by ≥ 1 of the following:~  * Serum monoclonal protein ≥ 1.0 g by protein electrophoresis~ * More than 200 mg of monoclonal protein in the urine on 24 hour electrophoresis~ * Serum immunoglobulin free light chain ≥ 10 mg/dL AND abnormal serum immunoglobulin kappa to lambda free light chain ratio~ * Monoclonal bone marrow plasmacytosis ≥ 30% (evaluable disease)~PATIENT CHARACTERISTICS:~* Eastern Cooperative Oncology Group (ECOG) performance status 0-3~* Absolute neutrophil count ≥ 1,000/μL~* Platelet count ≥ 75,000/μL~* Hemoglobin ≥ 8.0 g/dL~* CD4 \> 100/μL~* Creatinine ≤ 3 mg/dL~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No active malignancy with the exception of nonmelanoma skin cancer or in situ cervical or breast cancer~* No uncontrolled infection~* No other co-morbidity that would interfere with patient's ability to participate in trial~PRIOR CONCURRENT THERAPY:~* No limit to prior therapy~* At least 4 weeks since prior melphalan or other myelosuppressive agents~* At least 2 weeks since prior non-myelosuppressive agents (e.g., thalidomide or high-dose corticosteroids)~* No concurrent high-dose corticosteroids~  * Concurrent chronic steroids (maximum dose 20 mg/day prednisone equivalent) allowed if they are being given for disorders other than amyloid (e.g., adrenal insufficiency or rheumatoid arthritis)~ * Concurrent continuation of low level/stable steroid doses for replacement or inhalation therapy allowed~* Concurrent bisphosphonates allowed~* No concurrent immunosuppressive medications such as cyclosporine~* No other concurrent investigational treatment~* No concurrent cytotoxic chemotherapy or external-beam radiotherapy\>~* No other concurrent systemic anti-neoplastic therapy including, but not limited to, immunotherapy, hormonal therapy, or monoclonal antibody therapy~* No concurrent prophylactic hematopoietic growth factors (unless for treatment of an established cytopenia)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Anti-thymocyte Globulin/Melphalan (Type: EXPERIMENTAL): Anti-thymocyte Globulin (2.5 mg/Kg)and Melphalan (16 mg/m\^2)

Based on this trial design, predict the completion outcome and termination type (if applicable).